Breaking News
2 minutes ago
Simantini Singh Deo
Psyence Biomedical expands Australian sites from 3 to 5 for Phase IIb NPX-5 psilocybin trial in Adjustment Disorder in cancer patients, improving recruitment and study execution.
Simantini Singh Deo
Remedy Plan Therapeutics appoints Jotin Marango as CFO & CBO to drive financial strategy and support oncology pipeline growth, including advancement of its NAMPT inhibitor program.
Simantini Singh Deo
RenovoRx receives Japan Notice of Allowance for RenovoCath device enabling targeted drug delivery via vasa vasorum, strengthening its oncology platform and global IP portfolio.
Simantini Singh Deo
Spectral AI appoints David McGuire as CFO ahead of DeepView System commercialization in wound care, strengthening financial leadership to support growth and market expansion.
Simantini Singh Deo